Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure

Global bio-nanotech company pSivida Limited (NASDAQ:PSDV) (ASX:PSD) (Xetra:PSI) today announced the initiation of a Phase II clinical trial of Mifepristone (otherwise known as RU486) as an eye drop treatment for steroid associated elevated intraocular pressure (IOP).

The investigator-sponsored trial will involve up to 45 patients in the United States. pSivida will be supplying clinical trial material for this study and has filed a patent application on this product class.

Elevated IOP may occur in patients receiving steroidal treatment for chronic eye diseases. The trial will investigate the use of Mifepristone as a means to prevent elevation of IOP from intraocular steroid exposure. Mifepristone is a steroid receptor antagonist ("steroid blocker") already approved by the FDA. This study represents a potential new use of an existing drug, made possible by a new delivery system.

Link [www.pipelinereview.com/joomla/content/view/6596/109]

Related?

3 Responses to “Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure”

  1. a Says:

    very little market for this drug

  2. andrea Says:

    no much use for this drug

  3. Mary Says:

    I think it’s a marvellous step forward. So many people suffer from IOP due to use of corticosteroids used for a variety of medical conditions and IOP is one of those side-effects. Makes sense to prevent IOP via topical application. I use the drug 200mg daily for another medical condition and it’s safe, no side-effects even for use at that daily dose. Would absolutely recommend it as a safe and effective medication for various medical condtions. Those who claim there is no market for the drug don’t understand it.

Leave a Reply


Protected by Comment Guard Pro